JP2012509263A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509263A5
JP2012509263A5 JP2011536395A JP2011536395A JP2012509263A5 JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5 JP 2011536395 A JP2011536395 A JP 2011536395A JP 2011536395 A JP2011536395 A JP 2011536395A JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536395A
Other languages
English (en)
Japanese (ja)
Other versions
JP5518887B2 (ja
JP2012509263A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063370 external-priority patent/WO2010056588A1/en
Publication of JP2012509263A publication Critical patent/JP2012509263A/ja
Publication of JP2012509263A5 publication Critical patent/JP2012509263A5/ja
Application granted granted Critical
Publication of JP5518887B2 publication Critical patent/JP5518887B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536395A 2008-11-17 2009-11-05 四置換ピリダジンヘッジホッグ経路アンタゴニスト Expired - Fee Related JP5518887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11533208P 2008-11-17 2008-11-17
US61/115,332 2008-11-17
PCT/US2009/063370 WO2010056588A1 (en) 2008-11-17 2009-11-05 Tetrasubstituted pyridazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2012509263A JP2012509263A (ja) 2012-04-19
JP2012509263A5 true JP2012509263A5 (OSRAM) 2012-12-13
JP5518887B2 JP5518887B2 (ja) 2014-06-11

Family

ID=41722877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536395A Expired - Fee Related JP5518887B2 (ja) 2008-11-17 2009-11-05 四置換ピリダジンヘッジホッグ経路アンタゴニスト

Country Status (18)

Country Link
US (1) US8507490B2 (OSRAM)
EP (1) EP2358698B1 (OSRAM)
JP (1) JP5518887B2 (OSRAM)
KR (1) KR101342184B1 (OSRAM)
CN (1) CN102216285B (OSRAM)
AU (1) AU2009314349B2 (OSRAM)
BR (1) BRPI0921782A2 (OSRAM)
CA (1) CA2743483C (OSRAM)
CY (1) CY1113377T1 (OSRAM)
DK (1) DK2358698T3 (OSRAM)
EA (1) EA017386B1 (OSRAM)
ES (1) ES2392759T3 (OSRAM)
HR (1) HRP20120762T1 (OSRAM)
MX (1) MX2011005177A (OSRAM)
PL (1) PL2358698T3 (OSRAM)
PT (1) PT2358698E (OSRAM)
SI (1) SI2358698T1 (OSRAM)
WO (1) WO2010056588A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714872A2 (pt) * 2006-07-17 2013-03-19 Syngenta Participations Ag derivados de piridazina
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
CN102202737B (zh) 2008-11-03 2014-03-26 伊莱利利公司 二取代的2,3-二氮杂萘hedgehog通路拮抗剂
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CN110208424A (zh) * 2019-06-28 2019-09-06 江苏恒生检测有限公司 一种农药氟啶虫酰胺中含有杂质的分析方法
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
ES2162235T3 (es) 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv Piridazinaminas inhibidoras de la angiogenesis.
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO1999052534A1 (en) 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
AU780358B2 (en) 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102202737B (zh) 2008-11-03 2014-03-26 伊莱利利公司 二取代的2,3-二氮杂萘hedgehog通路拮抗剂
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012509263A5 (OSRAM)
JP2012530705A5 (OSRAM)
JP2012507535A5 (OSRAM)
JP2014139226A5 (OSRAM)
JP2009526072A5 (OSRAM)
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
JP2013537203A5 (OSRAM)
HRP20100477T1 (hr) Kemijski spojevi
JP2011527666A5 (OSRAM)
JP2011529054A5 (OSRAM)
JP2015524472A5 (OSRAM)
HRP20110962T1 (hr) Derivati pirazolil-aminopiridina korisni kao inhibitori kinaze
JP2014507464A5 (OSRAM)
JP2018502877A5 (OSRAM)
JP2012533546A5 (OSRAM)
JP2018507877A5 (OSRAM)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2010523692A5 (OSRAM)
JP2011519854A5 (OSRAM)
CA2579915A1 (en) Indole derivatives and their use as inhibitors of p53-mdm2 interaction
WO2009080836A3 (en) Macrocyclic indoles as hepatitis c virus inhibitors
JP2010533722A5 (OSRAM)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2010527365A5 (OSRAM)
JP2019518770A5 (OSRAM)